title: Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
abstract: Some cancer patients mount spontaneous T- and B-cell responses against their tumor cells. Autologous tumor reactive CD8 cytolytic T lymphocyte (CTL) and CD4 T-cell clones as well as antibodies from these patients have been used for the identification of genes encoding the target antigens. This knowledge opened the way for new approaches to the immunotherapy of cancer. In this review, we describe the characterization of the structure-function properties of the melanocyte/melanoma tumor antigen Melan-A/MART-1, the assessment of the T-cell repertoire available against this antigen in healthy individuals, and the analysis of naturally acquired and/or vaccine-induced CTL responses to this antigen in patients with metastatic melanoma.
authors.affiliation: Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland. pedro.romero@isrec.unil.ch
authors.forename: Pedro
authors.initials: P
authors.lastname: Romero
authors.forename: Danila
authors.initials: D
authors.lastname: Valmori
authors.forename: Mikael J
authors.initials: MJ
authors.lastname: Pittet
authors.forename: Alfred
authors.initials: A
authors.lastname: Zippelius
authors.forename: Donata
authors.initials: D
authors.lastname: Rimoldi
authors.forename: Frederic
authors.initials: F
authors.lastname: Lévy
authors.forename: Valérie
authors.initials: V
authors.lastname: Dutoit
authors.forename: Maha
authors.initials: M
authors.lastname: Ayyoub
authors.forename: Verena
authors.initials: V
authors.lastname: Rubio-Godoy
authors.forename: Olivier
authors.initials: O
authors.lastname: Michielin
authors.forename: Philippe
authors.initials: P
authors.lastname: Guillaume
authors.forename: Pascal
authors.initials: P
authors.lastname: Batard
authors.forename: Immanuel F
authors.initials: IF
authors.lastname: Luescher
authors.forename: Ferdy
authors.initials: F
authors.lastname: Lejeune
authors.forename: Danielle
authors.initials: D
authors.lastname: Liénard
authors.forename: Nathalie
authors.initials: N
authors.lastname: Rufer
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Dietrich
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Speiser
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Cerottini
mesh_terms: D000595:Amino Acid Sequence; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D016233:Immunotherapy, Active; D058965:MART-1 Antigen; D008545:Melanoma / Q000276:immunology* / Q000556:secondary / Q000628:therapy; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000737:chemistry / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology; D025941:Protein Interaction Mapping; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013329:Structure-Activity Relationship; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D011948:Receptors, Antigen, T-Cell